

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>(Use several sheets if necessary)</small>		<b>Applicant:</b> McSwiggen et al.	
		<b>Filing Date:</b> March 11, 2004	<b>Group:</b> 4636 1635

## U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
Attn	*	US 2003/0190635	10/2003	McSwiggen et al.	X	X	
Attn	*	US 2003/0206887	11/2003	Morrissey et al.	X	X	

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
Attn	1.	1325955	07/09/03	EP (Klippel-Giese et al.)				
	2.	08208687	08/1996	JP (Hotoda et al.)				
	3.	95/04142	02/09/95	WO (Robinson)				
	4.	01/097850	12/27/01	WO (Siemeister et al.)				
	5.	02/07747	01/31/02	WO (King)				
	6.	02/10378	02/07/02	WO (Cowser et al.)				
	7.	02/096927	12/05/02	WO (Escobdeo et al.)				
	8.	03/068797	08/21/03	WO (Rossi et al.)				
↓	9.	03/070910	08/28/03	WO (McSwiggen et al.)				

EXAMINER	Attn	DATE CONSIDERED	7/20/04
----------	------	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)			
<b>Applicant:</b> McSwiggen et al.			
<b>Filing Date:</b> March 11, 2004		<b>Group:</b> 1636 163	

Attn:	10.	03/080638	10/02/03	WO (Lacasse et al.)				
↓	11.	04/043977	05/27/04	WO (Prakush et al.)				
↓	12.	04/072261	08/26/04	WO (Li et al.)				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

Attn:	13.	Anderson et al., "Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance," <i>Oligonucleotides</i> , 13:303-312 (2003)
↓	14.	Bayard et al., "Increased stability and antiviral activity of 2'-O-phosphoglyceryl derivatives of (2'-5')oligo(adenylate)," <i>Eur. J. Biochem.</i> , 142(29):291-298 (1984)
↓	15.	International Search Report for PCT/US2004/016390 mailed March 31, 2005

EXAMINER	Attn: bow	DATE CONSIDERED	7/26/05
----------	-----------	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No.	Serial No.
				04-183 (400/147)	10/798,090
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)					
					
<b>Applicant:</b> McSwiggen et al.					
<b>Filing Date:</b> March 11, 2004		<b>Group:</b> 1635			

## U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
ATB	*	09/301,511	04/28/99	Beigleman et al.			
	*	09/740,332	12/18/00	Blatt et al.			
	*	09/800,594	03/06/01	Usman and McSwiggen			
	*	10/151,116	05/17/02	Matulic-Adamic et al.			
	*	10/201,394	08/13/01	Vargeese et al.			
	*	10/417,012	04/16/03	McSwiggen et al.			
	*	10/422,704	04/24/03	McSwiggen et al.			
	*	10/427,160	04/30/03	Vargeese et al.			
	*	10/444,853	05/23/03	McSwiggen et al.			
	*	10/652,791	08/29/03	McSwiggen et al.			
	*	10/693,059	10/23/03	McSwiggen et al.			
	*	10/720,448	11/24/03	McSwiggen et al.			
	*	10/727,780	12/03/03	Vaish et al.			
	*	10/757,803	01/14/04	Pavco et al.			
✓	*	10/780,447	02/13/04	Vargeese et al.			

EXAMINER <u>ATB</u>	DATE CONSIDERED <u>7/26/05</u>
---------------------	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: McSwiggen et al.	
(Use several sheets if necessary)		Filing Date: March 11, 2004	Group:

AttB	*	10/826,966	04/16/04	McSwiggen et al.			
	*	60/082,404	04/20/98	Thompson et al.			
	*	60/292,217	05/18/01	Adamic et al.			
	*	60/306,883	07/20/01	Vargeese et al.			
	*	60/311,865	08/13/01	Vargeese et al.			
	*	60/358,580	02/20/02	Beigelman et al.			
	*	60/362,016	03/06/02	Matulic-Adamic et al.			
	*	60/363,124	03/11/02	Beigelman et al.			
	*	60/386,782	06/06/02	Beigelman et al.			
	*	60/402,996	08/13/02	Usman et al.			
	*	60/406,784	08/29/02	Beigelman et al.			
	*	60/408,378	09/05/02	Beigelman et al.			
	*	60/409,293	09/09/02	Beigelman et al.			
	*	60/440,129	01/15/03	Beigelman et al.			
	*	60/543,480	02/10/04	Jadhati et al.			
	*	US 2001/0007666	01/05/99	Hoffman et al.			07/12/01
	*	US 2002/0130430	12/29/00	Caster			09/19/02
✓	*	US 2003/0077829	04/24/03	MacLachlan			
✓	*	US 2004/0037780	05/23/03	Klinghoffer et al.			04/22/04

EXAMINER <i>AttB</i>	DATE CONSIDERED <i>3/26/05</i>
----------------------	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-183 (400/147)	10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: March 11, 2004	Group:

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
ATB	*	4,501,729	02/26/1985	Boucher et al.			
	*	4,987,071	01/22/91	Cech et al.			
	*	5,108,921	04/28/92	Low et al.			
	*	5,138,045	08/11/92	Cook et al.			
	*	5,214,136	05/25/93	Lin et al.			
	*	5,334,711	08/02/94	Sproat			
	*	5,416,016	05/16/95	Low et al.			
	*	5,589,332	12/31/96	Shih et al.			
	*	5,624,803	04/29/1997	Noonberg et al.			
	*	5,627,053	05/06/97	Usman et al.			
	*	5,631,359	05/20/97	Chowrira et al.			
	*	5,631,360	05/20/97	Usman et al.			
	*	5,633,133	05/27/97	Long et al.			
	*	5,670,633	09/23/97	Cook et al.			
	*	5,672,695	09/30/97	Eckstein et al.			
↓	*	5,716,824	02/10/98	Beigelman et al.			

EXAMINER	<i>ATB</i>	DATE CONSIDERED	<i>2/26/95</i>
----------	------------	-----------------	----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No.	Serial No.
				04-183 (400/147)	10/798,090
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)					
<b>Applicant:</b> McSwiggen et al.					
<b>Filing Date:</b> March 11, 2004			<b>Group:</b>		

<i>Attn</i>	*	5,741,679	04/21/98	George et al.			
	*	5,792,847	08/11/98	Buhr et al.			
	*	5,804,683	09/08/98	Usman et al.			
	*	5,814,620	09/29/98	Robinson et al.			
	*	5,831,071	11/03/98	Usman et al.			
	*	5,834,186	11/10/98	George et al.			
	*	5,849,902	12/15/98	Arrow et al.			
	*	5,854,038	12/29/98	Sullenger et al.			
	*	5,871,914	02/16/99	Nathan et al.			
	*	5,889,136	03/30/99	Scaringe et al.			
	*	5,898,031	04/27/99	Crooke			
	*	5,902,880	05/11/99	Thompson et al.			
	*	5,968,909	10/19/99	Agrawal et al.			
	*	5,989,912	11/23/99	Arrow et al.			
	*	5,998,203	12/07/99	Adamic et al.			
	*	6,001,311	12/14/99	Brennan			
	*	6,005,087	12/21/99	Cook et al.			
	*	6,008,400	12/28/99	Scaringe et al.			
	*	6,054,576	04/25/00	Bellon et al.			

EXAMINER	<i>Attn</i>	DATE CONSIDERED	<i>4/26/05</i>
----------	-------------	-----------------	----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		04-183 (400/147)	10/798,090
(Use several sheets if necessary)		Applicant:	
		McSwiggen et al.	
		Filing Date:	Group:
		March 11, 2004	

<i>NTB</i>	*	6,107,094	08/22/00	Crooke			
	*	6,111,086	08/29/00	Scaringe et al.			
	*	6,117,657	09/12/00	Usman et al.			
	*	6,146,886	11/14/2000	Thompson et al.			
	*	6,153,737	11/28/00	Manoharan et al.			
	*	6,162,909	12/19/00	Bellon et al.			
	*	6,168,778	01/02/01	Janjic et al.			
	*	6,180,613	01/30/01	Kaplitt et al.			
	*	6,235,310	05/22/01	Wang et al.			
	*	6,235,886	05/22/01	Manoharan et al.			
	*	6,248,878	06/19/01	Adamic et al.			
	*	6,300,074	10/09/01	Gold			
	*	6,303,773	10/16/01	Bellon et al.			
	*	6,335,434	01/01/02	Guzaev et al.			
	*	6,353,098	03/05/02	Usman et al.			
	*	6,362,323	03/26/02	Usman et al.			
	*	6,395,492	05/28/02	Manoharan et al.			
	*	6,395,713	05/28/02	Beigelman et al.			
	*	6,437,117	08/20/02	Usman et al.			

EXAMINER	<i>John</i>	DATE CONSIDERED	<i>3/26/08</i>
----------	-------------	-----------------	----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No.	Serial No.
				04-183 (400/147)	10/798,090
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)					
<b>Applicant:</b> McSwiggen et al.					
<b>Filing Date:</b> March 11, 2004			<b>Group:</b>		

ATB	*	6,447,796	09/10/02	Vook et al.			
	*	6,469,158	10/22/02	Usman et al.			
	*	6,476,205	11/05/02	Buhr et al.			
	*	6,506,559	06/14/03	Fire et al.			
	*	6,528,631	03/04/03	Cook et al.			
	*	6,565,885	05/20/2003	Tarara et al.			
	*	6,582,728	06/24/2003	Platz et al.			
	*	6,586,524	07/01/03	Sagara			
	*	6,592,904	07/15/2003	Platz et al.			
ATB	*	6,617,156	09/09/03	Doucette-Stamm et al.			

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
ATB	*	2001240375 (Old Application No. 40375/01)	03/16/01	AU (Graham et al.)				
ATB	*	2,359,180	08/03/00	CA (Kreutzer et al.)				

EXAMINER	<i>ATB</i>	DATE CONSIDERED	<i>9/12/04</i>
----------	------------	-----------------	----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: McSwiggen et al.	
(Use several sheets if necessary)		Filing Date: March 11, 2004	Group:

<i>Altman</i>	*	1144623 B1	01/29/02	EP (Kreutzer et al.)				
	*	0 360 257	02/28/90	EP (Hampel et al.)				
	*	88/09810	12/15/88	WO (Tullis et al.)				
	*	89/02439	03/23/89	WO (Arnold et al.)				
	*	90/12096	10/18/90	WO (Low et al.)				
	*	90/14090	11/29/90	WO (Gillespie et al.)				
	*	91/03162	03/21/91	WO (Rossi et al.)				
	*	92/07065	04/30/92	WO (Eckstein et al.)				
	*	93/15187	08/05/93	WO (Usman et al.)				
	*	93/23569	11/25/93	WO (Draper et al.)				
	*	94/01550	01/20/94	WO (Agrawal et al.)				
	*	94/02595	02/03/94	WO (Sullivan et al.)				
	*	95/06731	03/09/95	WO (Usman et al.)				
	*	95/11304	04/27/95	WO (Usman et al.)				
	*	95/11910	05/04/95	WO (Dudycz et al.)				
	*	96/10390	04/11/96	WO (Ansell et al.)				
	*	96/10391	04/11/96	WO (Choi et al.)				
	*	96/10392	04/11/96	WO (Holland et al.)				
<i>Altman</i>	1	96/18736	06/20/96	WO (Beigelman et al.)				

EXAMINER	<i>Altman</i>	DATE CONSIDERED <i>7/26/05</i>
----------	---------------	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: McSwiggen et al.	
(Use several sheets if necessary)		Filing Date: March 11, 2004	Group:

<i>ATB</i>	*	96/22689	08/01/96	WO (Pyle et al.)				
	*	97/26270	07/24/97	WO (Beigelman et al.)				
	*	98/13526	04/02/98	WO (Woolf et al.)				
	*	98/27104	06/25/98	WO (Breaker et al.)				
	*	98/28317	07/02/98	WO (Matulic-Adamic et al.)				
	*	98/43993	10/08/98	WO (Breaker et al.)				
	*	98/58058	12/23/98	WO (Ludwig & Sproat)				
	*	99/04819	02/04/99	WO (Klimuk)				
	*	99/05094	02/04/99	WO (Beigelman et al.)				
	*	99/07409	02/18/99	WO (Deschamps de Paillette et al.)				
	*	99/14226	03/25/99	WO (Wengel et al.)				
	*	99/16871	04/08/99	WO (Eckstein et al.)				
	*	99/17120	04/08/99	WO (Davis and Bishop)				
	*	99/29842	06/17/99	WO (Sullenger et al.)				
	*	99/31262	06/24/99	WO (Barry et al.)				
	*	99/32619	07/01/99	WO (Fire et al.)				
	*	99/49029	09/30/99	WO (Graham et al.)				
	*	99/53050	10/21/99	WO (Waterhouse et al.)				
<i>↓</i>	*	99/54459	10/28/99	WO (Thompson et al.)				

EXAMINER <i>ATB</i>	DATE CONSIDERED <i>3/26/05</i>
---------------------	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No.	Serial No.
				04-183 (400/147)	10/798,090
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)					
<b>Applicant:</b> McSwiggen et al.					
			<b>Filing Date:</b>	<b>Group:</b>	
			March 11, 2004		


<i>Attn:</i>	*	99/55857	11/04/99	WO (Beigelman et al.)				
	*	99/61631	12/02/99	WO (Heifetz et al.)				
	*	99/66063	12/23/99	WO (Manoharan et al.)				
	*	00/01846	01/13/00	WO (Plaetinck et al.)				
	*	00/17369	03/30/00	WO (Gurney et al.)				
	*	00/24931	05/04/00	WO (Nathan and Ellington)				
	*	00/26226	05/11/00	WO (Breaker et al.)				
	*	00/44895	08/03/00	WO (Kreutzer et al.)				
	*	00/44914	08/03/00	WO (Li et al.)				
	*	00/49035	08/24/00	WO (Sheen)				
	*	00/53722	09/14/00	WO (O'Hare and Normand)				
	*	00/63364	10/26/00	WO (Pachuk et al.)				
	*	00/66604	11/09/00	WO (Wengel et al.)				
	*	01/04313	01/18/01	WO (Satishchandran et al.)				
	*	01/29058	04/26/01	WO (Mello et al.)				
	*	01/36646	05/25/01	WO (Zernicka-Goetz et al.)				
	*	01/38551	05/31/01	WO (Grossniklaus)				
	*	01/42443	06/14/01	WO (Churikov et al.)				
<i>V</i>	*	01/49844	07/12/01	WO (Driscoll et al.)				

EXAMINER	<i>Attn:</i>	DATE CONSIDERED
----------	--------------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: McSwiggen et al.	
(Use several sheets if necessary)		Filing Date: March 11, 2004	Group:

04-183	*	01/53475	07/26/01	WO (Cogoni et al.)				
	*	01/68836	09/20/01	WO (Beach et al.)				
	*	01/70944	09/27/01	WO (Honer et al.)				
	*	01/70949	09/27/01	WO (Graham et al.)				
	*	01/72774	10/04/01	WO (Deak et al.)				
	*	01/75164	10/11/01	WO (Tuschl et al.)				
	*	01/92513	12/06/01	WO (Arndt et al.)				
	*	01/96584	12/20/01	WO (Mushegian et al.)				
	2	01/029176	04/26/01	WO (Choi et al.)				
	*	02/22636	03/21/02	WO (Bennett et al.)				
	*	02/38805	05/16/02	WO (Echeverri et al.)				
	*	02/44321	06/06/02	WO (Tuschl et al.)				
	*	02/55692	07/18/02	WO (Kreutzer et al.)				
	*	02/55693	07/18/02	WO (Kreutzer et al.)				
	*	02/094185 (PCT/US02/15876)	11/28/02	WO (Beigelman et al.)				
	*	03/024420	03/27/03	WO (Ahlheim et al.)				
	*	03/046185	06/05/03	WO (Wang et al.)				
	*	03/047518	06/12/03	WO (Wang et al.)				
Y	*	03/064625	08/07/03	WO (Woolf et al.)				

EXAMINER		DATE CONSIDERED	
----------	---	-----------------	---

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: McSwiggen et al.	
(Use several sheets if necessary)		Filing Date: March 11, 2004	Group:

1	*	03/064626	08/07/03	WO (Woolf et al.)				
	*	03/070918 (PCT/US03/05346)	08/28/03	WO (McSwiggen et al.)				
	*	03/074654 (PCT/US03/05028)	09/12/03	WO (McSwiggen et al.)				
	*	04/013280	02/12/04	WO (Davidson et al.)				
	3	PCT/US04/13456	04/30/04	WO (Vargeese et al.)				
✓	4	PCT/US04/16390	05/24/04	WO (Vaish et al.)				






## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).


1	*	Abramovitz et al., "Catalytic Role of 2'-Hydroxyl Groups Within a Group II Intron Active Site," <i>Science</i> 271:1410-1413 (1996)
	*	Adah et al., "Chemistry and Biochemistry of 2',5'-Oligoadenylate-Based Antisense Strategy," <i>Current Medicinal Chemistry</i> , 8, 1189-1212 (2001)
	*	Akhtar and Juliano, "Cellular Uptake and Intracellular Fate of AntiSense Oligonucleotides," <i>Trends Cell Biol.</i> 2:139-144 (1992)
	*	Aldrian-Herrada et al., "A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a <i>retro-inverso</i> delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons," <i>Nucleic Acids Research</i> 26:4910-4916 (1998)
	*	Allshire, "RNAi and Heterochromatin – A Hushed-up Affair," <i>Science</i> 297:1818-1819 (2002)
✓	*	Andrews and Faller, "A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells," <i>Nucleic Acids Research</i> 19:2499 (1991)

EXAMINER	<i>Anthony</i>	DATE CONSIDERED	<i>7/26/05</i>
----------	----------------	-----------------	----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: McSwiggen et al.	
(Use several sheets if necessary)		Filing Date: March 11, 2004	Group:

       	• Antopolksy et al., "Peptide-Oligonucleotide Phosphorothioate Conjugates with Membrane Translocation and Nuclear Localization Properties," <i>Bioconjugate Chem.</i> 10:598-606 (1999)
	• Arap et al., "Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model," <i>Science</i> 279:377-380 (1998)
	• Baenziger and Fiete, "Galactose and N-Acetylgalactosamine-Specific Endocytosis of Glycopeptides by Isolated Rat Hepatocytes," <i>Cell</i> 22:611-620 (1980)
	• Bahramian et al., "Transcriptional and Posttranscriptional Silencing of Rodent $\alpha 1(I)$ Collagen by a Homologous Transcriptionally Self-Silenced Transgene," <i>Molecular and Cellular Biology</i> , 274:283 (1999)
	• Banerjee and Turner, "The Time Dependence of Chemical Modification Reveals Slow Steps in the Folding of a Group I Ribozyme," <i>Biochemistry</i> 34:6504-6512 (1995)
	• Bannai et al., "Effect of Injection of Antisense of Oligodeoxynucleotides of GAD Isozymes into Rat Ventromedial Hypothalamus on Food Intake and Locomotor Activity," <i>Brain Research</i> 784:305-315 (1998)
	• Bannai et al., "Water-absorbent Polymer as a Carrier for a Discrete Deposit of Antisense Oligodeoxynucleotides in the Central Nervous System," <i>Brain Research Protocols</i> 3:83-87 (1998)
	• Bartel and Szostak, "Isolation of New Ribozymes from a Large Pool of Random Sequences," <i>Science</i> 261:1411-1418 (1993)
	• Basi et al., "Antagonistic Effects of $\beta$ -Site Amyloid Precursor Protein-cleaving Enzymes 1 and 2 on $\beta$ -Amyloid Peptide Production in Cells*," <i>The Journal of Biological Chemistry</i> , 278, 31512-31520 (2003)
	• Bass, "Double-Stranded RNA as a Template for Gene Silencing," <i>Cell</i> , 101, 235-238 (2000)
	• Bass, "The short answer," <i>Nature</i> 411:428-429 (2001)

EXAMINER		DATE CONSIDERED	
----------	---	-----------------	---

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.


FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: McSwiggen et al.	
(Use several sheets if necessary)		Filing Date: March 11, 2004	Group:


<p><i>Attb</i></p>	* Beaucage and Iyer, "The Functionalization of Oligonucleotides Via Phosphoramidite Derivatives," <i>Tetrahedron</i> 49:1925-1963 (1993)
	* Beaudry and Joyce, "Directed Evolution of an RNA Enzyme," <i>Science</i> 257:635-641 (1992)
	* Beigelman et al., "Chemical Modification of Hammerhead Ribozymes," <i>The Journal of Biological Chemistry</i> 270:25702-25708 (1995)
	* Bellon et al., "Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes," <i>Nucleosides &amp; Nucleotides</i> 16:951-954 (1997)
	* Bellon et al., "Post-synthetically Ligated Ribozymes: An Alternative Approach to Iterative Solid Phase Synthesis," <i>Bioconjugate Chem.</i> 8:204-212 (1997)
	* Bernstein et al., "Role for a Bidentate Ribonuclease in the Initiation Step of RNA Interference," <i>Nature</i> 409:363-366 (2001)
	* Berzal-Herranz et al., "Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme," <i>EBMO J.</i> 12:2567-2574 (1993)
	* Berzal-Herranz et al., "In vitro selection of active hairpin ribozymes by sequential RNA-catalyzed cleavage and ligation reactions," <i>Genes &amp; Development</i> 6:129-134 (1992)
	* Bettinger et al., "Size Reduction of Galactosylated PEI/DNA Complexes Improves Lectin-Mediated Gene Transfer into Hepatocytes," <i>Bioconjugate Chem.</i> , 10, 558-561 (1999)
	* Bevilacqua et al., "A Mechanistic Framework for the Second Step of Splicing Catalyzed by the <i>Tetrahymena</i> Ribozyme," <i>Biochemistry</i> 35:648-568 (1996)
	* Boado et al., "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," <i>Journal of Pharmaceutical Sciences</i> 87:1308-1315 (1998)
	* Boado, "Antisense drug delivery through the blood-brain barrier," <i>Advanced Drug Delivery Reviews</i> 15:73-107 (1995)
	* Bongartz et al., "Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide," <i>Nucleic Acids Research</i> 22:4681-4688 (1994)

EXAMINER	<i>Attb</i>	DATE CONSIDERED	<i>7/26/05</i>
----------	-------------	-----------------	----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: March 11, 2004	Group:

	* Bonora et al., "Biological Properties of Antisense Oligonucleotides Conjugated to Different High-Molecular Mass Poly(ethylene glycols)," <u>Nucleosides &amp; Nucleotides</u> 18:1723-1725 (1999)
	* Bonora et al., "Synthesis and Characterization of High-Molecular Mass Polyethylene Glycol-Conjugated Oligonucleotides," <u>Bioconjugate Chem.</u> 8:793-797 (1997)
	* Breaker and Joyce, "Inventing and improving ribozyme function: rational design versus iterative selection methods," <u>TIBTECH</u> 12:268-275 (1994)
	* Breaker et al., "A DNA enzyme with Mg <sup>2+</sup> -dependent RNA phosphoesterase activity," <u>Chemistry &amp; Biology</u> 2(10):655-660 (1995)
	* Breaker, "Are engineered proteins getting competition from RNA?" <u>Current Opinion in Biotechnology</u> 7:442-448 (1996)
	* Breaker, "Catalytic DNA: in training and seeking employment," <u>Nature Biotechnology</u> 17:422-423 (1999)
	* Brennan et al., "Two-Dimensional Parallel Array Technology as a New Approach to Automated Combinatorial Solid-Phase Organic Synthesis," <u>Biotechnology and Bioengineering (Combinatorial Chemistry)</u> 61:33-45 (1998)
	* Broaddus et al., "Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion," <u>Neurosurg. Focus</u> 3(5):Article 4 (1997)
	* Broaddus et al., "Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion," <u>J Neurosurg</u> 88:734-742 (1998)
	* Brody and Gold, "Aptamers as therapeutic and diagnostic agents," <u>Reviews in Molecular Biotechnology</u> 74:5-13 (2000)
	* Buckwold et al., "Effects of a Naturally Occurring Mutation in the Hepatitis B Virus Basal Core Promoter on Precore Gene Expression and Viral Replication," <u>Journal of Virology</u> , 5845-5851 (1996)

EXAMINER 	DATE CONSIDERED 
---	---

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> (Rev. 2-32)	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b>	<b>Serial No.</b>
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		04-183 (400/147)	10/798,090
(Use several sheets if necessary)			
<b>Applicant:</b>			
McSwiggen et al.			
<b>Filing Date:</b>		<b>Group:</b>	
March 11, 2004			

<p style="margin: 0;"><i>AlkB</i></p> <p style="margin: 0;">↓</p>	<ul style="list-style-type: none"> <li>* Burger et al., "Experimental Corneal Neovascularization: Biomicroscopic, Angiographic, and Morphologic Correlation," <i>Cornea</i> 4:35-41 (1985/1986)</li> <li>* Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates," <i>Biochemistry</i> 35:14090-14097 (1996) (volume no. mistakenly listed as 6)</li> <li>* Burlina et al., "Chemical Engineering of RNase Resistant and Catalytically Active Hammerhead Ribozymes," <i>Bioorganic &amp; Medicinal Chemistry</i> 5:1999-2010 (1997)</li> <li>* Caruthers et al., "Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs," <i>Methods in Enzymology</i> 211:3-19 (1992)</li> <li>* Cebon et al., "New DNA Modification Strategies Involving Oxime Formation," <i>Aust. J. Chem.</i> 53:333-339 (2000)</li> <li>* Cech, "Ribozymes and Their Medical Implications," <i>JAMA</i> 260:3030-3034 (1988)</li> <li>* Chaloin et al., "Design of Carrier Peptide-Oligonucleotide Conjugates With Rapid Membrane Translocation and Nuclear Localization Properties," <i>BBRC</i> 243:601-608 (1998)</li> <li>* Chartrand et al., "An oligodeoxyribonucleotide that supports catalytic activity in the hammerhead ribozyme domain," <i>Nucleic Acids Research</i> 23(20):4092-4096 (1995)</li> </ul>
<p style="margin: 0;">5</p>	<ul style="list-style-type: none"> <li>Chen et al., "Multitarget-Ribozyme Directed to Cleave at up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication-Potential Effectiveness Against Most Presently Sequenced HIV-1 Isolates," <i>Nucleic Acids Research</i> 20:4581-4589 (1992)</li> </ul>
<p style="margin: 0;">*</p>	<ul style="list-style-type: none"> <li>Chiu et al., "siRNA function in RNAi: A chemical modification analysis," <i>RNA</i>, 9:1034-1048 (2003)</li> </ul>
<p style="margin: 0;">6</p>	<ul style="list-style-type: none"> <li>Choi et al., "Effect of Poly(ethylene glycol) Grafting on Polyethylenimine as a Gene Transfer Vector <i>in vitro</i>," <i>Bull. Korean Chem. Soc.</i>, 22, 46-52 (2001)</li> </ul>

EXAMINER		DATE CONSIDERED	
----------	---	-----------------	---

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: March 11, 2004	Group:

<i>Attm</i>	*	Chowrira et al., "Novel guanosine requirement for catalysis by the hairpin ribozyme," <i>Nature</i> 354:320-322 (1991)
	*	Chun et al., "Effect of infusion of vasoactive intestinal peptide (VIP)-antisense oligodeoxynucleotide into the third cerebral ventricle above the hypothalamic cuprachiasmatic nucleus on the hyperglycemia caused by intracranial injection of 2-deoxy-D-glucose in rats," <i>Neuroscience Letters</i> 257:135-138 (1998)
	*	Clemens et al., "The Double-Stranded RNA-Dependent Protein Kinase PKR: Structure and Function," <i>Journal of Interferon and Cytokine Research</i> , 17:503-524 (1997)
	*	Cload and Schepartz, "Polyether Tethered Oligonucleotide Probes," <i>J. Am. Chem. Soc.</i> 113:6324-6326 (1991)
	*	Collins and Olive, "Reaction Conditions and Kinetics of Self-Cleavage of a Ribozyme Derived From <i>Neurospora</i> VS RNA," <i>Biochemistry</i> 32:2795-2799 (1993)
	*	Connolly et al., "Binding and Endocytosis of Cluster Glycosides by Rabbit Hepatocytes," <i>The Journ. of Biol. Chem.</i> 257:939-945 (1982)
	*	Conry et al., "Phase I Trial of a Recombinant Vaccinia Virus Encoding Carcinoembryonic Antigen in Metastatic Adenocarcinoma: Comparison of Intradermal versus Subcutaneous Administration," <i>Clinical Cancer Research</i> 5:2330-2337 (1999)
	7	Couture and Stinchcomb, "Anti-gene therapy: the use of ribozymes to inhibit gene function," <i>Trends In Genetics</i> 12:510-515 (1996)
	*	Crooke, "Advances in Understanding the Pharmacological Properties of Antisense Oligonucleotides," <i>Advances in Pharmacology</i> 40:1-49 (1997)
	*	Crooke, "Antisense Therapeutics," <i>Biotechnology and Genetic Engineering Reviews</i> 15:121-157 (1998)
	*	Crooke, "Progress in Antisense Technology: The End of the Beginning," <i>Methods in Enzymology</i> 313:3-45 (1999)
<i>Attm</i>	*	d'Aldin et al., "Antisense oligonucleotides to the GluR2 AMPA receptor subunit modify excitatory synaptic transmission in vivo," <i>Molecular Brain Research</i> 55:151-164 (1998)

EXAMINER <i>Attm</i>	DATE CONSIDERED <i>Mar 10</i>
----------------------	-------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: March 11, 2004	Group:

<i>Attn:</i>	*	Daniels et al., "Two Competing Pathways for Self-splicing by Group II Introns: A Quantitative Analysis of <i>in Vitro</i> Reaction Rates and Products," <i>J. Mol. Biol.</i> 256:31-49 (1996)
	8	Dawkins et al., "Animal models of chronic obstructive pulmonary disease," <i>Thorax</i> , 56:972-977 (2001)
	*	Defrancq and Lhomme, "Use of an Aminooxy Linker for the Functionalization of Oligodeoxyribonucleotides," <i>Bioorganic &amp; Medicinal Chem. Lett.</i> 11:931-933 (2001)
	*	Delihas et al., "Natural antisense RNA/target RNA interactions: Possible models for antisense oligonucleotide drug design," <i>Nature Biotechnology</i> 15:751-753 (1997)
	*	Diebold et al., "Mannose Polyethylenimine Conjugates for Targeted DNA Delivery into Dendritic Cells*," <i>The Journal of Biological Chemistry</i> , 274, 19087-19094 (1999)
	9	Dropulic et al., "Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type I Expression," <i>Journal of Virology</i> 66:1432-1441 (1992)
	*	Dryden et al., "The lack of specificity of neuropeptide Y (NPY) antisense oligodeoxynucleotides administered intracerebroventricularly in inhibiting food intake and NPY gene expression in the rat hypothalamus," <i>Journal of Endocrinology</i> 157:169-175 (1998)
	*	Durand et al., "Circular Dichroism Studies of an Oligodeoxyribonucleotide Containing a Hairpin Loop Made of a Hexaethylene Glycol Chain: Conformation and Stability," <i>Nucleic Acids Research</i> 18:6353-6359 (1990) [sometimes referred to as Seela and Kaiser]
	*	Duval-Valentin, "Specific inhibition of transcription by triple helix-forming oligonucleotides," <i>Proc. Natl. Acad. Sci. USA</i> 89:504-508 (1992)
	*	Earnshaw et al., "Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and Function," <i>Biopolymers</i> 48:39-55 (1998)
<i>↓</i>	*	Edbauer et al., Resenilin and nicastrin regulate each other and determine amyloid $\beta$ -peptide production via complex formation," <i>PNAS</i> , 99, 8666-8671 (2002)

EXAMINER: <i>Attn:</i>	DATE CONSIDERED: <i>3/16/05</i>
------------------------	---------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)			
<b>Applicant:</b> McSwiggen et al.			
<b>Filing Date:</b> March 11, 2004		<b>Group:</b>	

OHB	* 10	Egholm et al., "PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules," <i>Nature</i> 365:566-568 (1993)
		Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> 411:494-498 (2001)
	*	Elbashir et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in <i>Drosophila Melanogaster</i> Embryo Lysate," <i>The EMBO Journal</i> 20:6877-6888 (2001)
	*	Elbashir et al., "RNA Interference is Mediated by 21- and 22-Nucleotide RNAs," <i>Genes and Development</i> 15:188-200 (2001)
	*	Elkins and Rossi, "Ch. 2 - Cellular Delivery of Ribozymes," in <i>Delivery Strategies for Antisense Oligonucleotide Therapeutics</i> , edited by Akhtar, CRC Press, pp. 17-220 (1995)
	10	Elroy-Stein and Moss, "Cytoplasmic Expression System Based on Constitutive Synthesis of Bacteriophage T7 RNA Polymerase in Mammalian Cells," <i>Proc. Natl. Acad. Sci. USA</i> 87:6743-6747 (1990)
	*	Emerich et al., "Biocompatibility of Poly (DL-Lactide-co-Glycolide) Microspheres Implanted Into the Brain," <i>Cell Transplantation</i> 8:47-58 (1999)
	*	Epa et al., "Downregulation of the p75 Neurotrophin Receptor in Tissue Culture and <i>In Vivo</i> , Using $\beta$ -Cyclodextrin-Adamantane-Oligonucleotide Conjugates," <i>Antisense and Nucleic Acid Drug Dev.</i> 10:469-478 (2000)
	*	Erbacher et al., "Transfection and physical properties of various saccharide, poly(ethylene glycol), and antibody-derivatized polyethylenimines (PEI)," <i>The Journal of Gene Medicine</i> , 1, 210-222 (1999) [sometimes incorrectly cited as pages 1-18]
	*	Feldstein et al., "Two sequences participating in the autolytic processing of satellite tobacco ringspot virus complementary RNA," <i>Gene</i> 82:53-61 (1989)
▼	*	Ferentz and Verdine, "Disulfided Cross-Linked Oligonucleotides," <i>J. Am. Chem. Soc.</i> 113:4000-4002 (1991)

EXAMINER	<i>Ottoboni</i>	DATE CONSIDERED	<i>7/26/05</i>
----------	-----------------	-----------------	----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: March 11, 2004	Group:

<i>Altb</i>	*	Filion and Phillips, "Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells," <i>Biochimica et Biophysica Acta</i> 1329:345-356 (1997)
	*	Findeis, "Stepwise Synthesis of a GalNAc-containing Cluster Glycoside Ligand of the Asialoglycoprotein Receptor," <i>Int. J. Peptide Protein Res.</i> 43:477-485 (1994)
	*	Fire et al., "Potent and Specific Genetic Interference by Double-Stranded RNA in <i>Caenorhabditis Elegans</i> ," <i>Nature</i> 391:806-811(1998)
	*	Fire, "RNA-triggered Gene Silencing," <i>TIG</i> 15:358-363(1999)
	*	Forster and Altman, "External Guide Sequences for an RNA Enzyme," <i>Science</i> 249:783-786 (1990)
	*	Fox, "Targeting DNA with Triplexes," <i>Current Medicinal Chemistry</i> 7:17-37 (2000)
	*	Freier et al., "Improved free-energy parameters for predictions of RNA duplex stability," <i>Proc. Natl. Acad. Sci. USA</i> 83:9373-9377 (1986) [sometimes referred to as Frier]
	*	Furgeson et al., "Modified Linear Polyethylenimine—Cholesterol Conjugates for DNA Complexation," <i>Bioconjugate Chem.</i> , 14, 840-847 (2003)
	*	Futami et al., "Induction of apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2," <i>Nucleic Acids Research Supplement</i> , 251-252 (2002)
11	Gao and Huang, "Cytoplasmic Expression of a Reporter Gene by Co-Delivery of T7 RNA Polymerase and T7 Promoter Sequence with Cationic Liposomes," <i>Nucleic Acids Research</i> 21:2867-2872 (1993)	
	*	GenBank Accession No. AB020693
12	Genbank Accession No. AB041395	
	*	GenBank Accession No. AF037412
	*	GenBank Accession No. AF063658
	*	Genbank Accession No. AF100308.1
13	Genbank Accession No. AF279779	
14	Genbank Accession No. AF385589	

EXAMINER <i>Altb</i>	DATE CONSIDERED <i>Altb 18</i>
-------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)			
<b>Applicant:</b> McSwiggen et al.			
<b>Filing Date:</b> March 11, 2004		<b>Group:</b>	

15	Genbank Accession No. AF498917
*	GenBank Accession No. AJ430458
16	Genbank Accession No. AK074575
*	GenBank Accession No. D00239
*	GenBank Accession No. D11168
*	GenBank Accession No. D50483.1
*	GenBank Accession No. K02121
*	GenBank Accession No. L24917
*	GenBank Accession No. L38318
*	GenBank Accession No. M16248
*	GenBank Accession No. M31724
*	GenBank Accession No. NC 001345
*	GenBank Accession No. NC 001347
*	GenBank Accession No. NC 001353
*	GenBank Accession No. NC 001563
*	GenBank Accession No. NC 001781
17	Genbank Accession No. NM 000740
*	GenBank Accession No. NM 001285
*	GenBank Accession No. NM 001982
*	GenBank Accession No. NM 002592.1
*	GenBank Accession No. NM 002667
*	GenBank Accession No. NM 002737
*	GenBank Accession No. NM 003219
*	Genbank Accession No. NM 003376.1
*	GenBank Accession No. NM 004283
*	GenBank Accession No. NM 004448

EXAMINER	<i>John</i>	DATE CONSIDERED	<i>7/26/05</i>
----------	-------------	-----------------	----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: McSwiggen et al.	
(Use several sheets if necessary)		Filing Date: March 11, 2004	Group:

OHB	* GenBank Accession No. NM 005228
	* GenBank Accession No. NM 005235
	* GenBank Accession No. S82227
18	Genbank Accession No. U29589
	* GenBank Accession No. U51188
	* GenBank Accession No. U86046
	* GenBank Accession No. X01087
	* GenBank Accession No. X02316
	* GenBank Accession No. X07203
19	Genbank Accession No. X15266
	* GenBank Accession No. X60667
	* GenBank Accession No. XM 015620
	* GenBank Accession No. XM 033884
	* GenBank Accession No. XM 067723
	* Ghirnikar et al., "Chemokine inhibition in rat stab wound brain injury using antisense oligodeoxynucleotides," <i>Neuroscience Letters</i> 247:21-24 (1998)
	* Godbey et al., "Poly(ethylenimine) and its role in gene delivery," <i>Journal of Controlled Release</i> , 60, 149-160 (1999)
	* Godbey et al., "Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery," <i>Proc. Natl. Acad. Sci. USA</i> , 96, 5177-5181 (1999)
	* Godwin et al., "The Synthesis of Biologically Active Pteroylolo- $\gamma$ -L-Glutamates (Folic Acid Conjugates)," <i>The Journal of Biological Chemistry</i> 247:2266-2271 (1972)
	* Gold et al., "Diversity of Oligonucleotide Functions," <i>Annu. Rev. Biochem.</i> 64:763-797 (1995)
✓	* Gold, "Axonal Regeneration of Sensory Nerves is Delayed by Continuous Intrathecal Infusion of Nerve Growth Factor," <i>Neuroscience</i> 76:1153-1158 (1997)

EXAMINER	<i>OHB</i>	DATE CONSIDERED	<i>3/26/05</i>
----------	------------	-----------------	----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: March 11, 2004	Group:

Attn: B	*	Gonzalez et al., "New Class of Polymers for the Delivery of Macromolecular Therapeutics," <i>Bioconjugate Chem.</i> , 10, 1068-1074 (1999)
	20	Good et al., "Expression of small, therapeutic RNAs in human nuclei," <i>Gene Therapy</i> 4:45-54 (1997)
	*	Grant et al., "Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor," <i>Diabetologia</i> 36:282-291 (1993)
	*	Grasby et al., "Purine Functional Groups in Essential Residues of the Hairpin Ribozyme Required for Catalytic Cleavage of RNA," <i>Biochemistry</i> 34:4068-4076 (1995)
	*	Griffin et al., "Group II intron ribozymes that cleave DNA and RNA linkages with similar efficiency, and lack contacts with substrate 2'-hydroxyl groups," <i>Chemistry &amp; Biology</i> 2:761-770 (1995)
	21	Grubb et al., "Pathophysiology of Gene-Targeted Mouse Models for Cystic Fibrosis," <i>Physiological Reviews</i> , 79, Supp. No. 1, S193-S214 (1999)
	*	Guerrier-Takada et al., "The RNA Moiety of Ribonuclease P Is the Catalytic Subunit of the Enzyme," <i>Cell</i> 35:849-857 (1983)
	*	Guo and Collins, "Efficient <i>trans</i> -cleavage of a stem-loop RNA substrate by a ribozyme derived from <i>Neurospora</i> VS RNA," <i>EMBO J.</i> 14:368-376 (1995)
	*	Habus et al., "A Mild and Efficient Solid-Support Synthesis of Novel Oligonucleotide Conjugates," <i>Bioconjugate Chem.</i> 9:283-291 (1998)
	*	Hall et al., "Establishment and Maintenance of a Heterochromatin Domain," <i>Science</i> 297:2232-2237 (2002)
	22	Hall, "Pharmacogenetics, pharmacogenomics and airway disease," <i>Respir. Res.</i> , 3:10 (2002)
↓	*	Hamilton, et al., "A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants," <i>Science</i> , 286, 950-952 (1999))

EXAMINER <i>Attn: B</i>	DATE CONSIDERED <i>7/10/05</i>
----------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)			
<b>Applicant:</b> McSwiggen et al.			
<b>Filing Date:</b> March 11, 2004		<b>Group:</b>	

<i>Attn:</i>	*	Hammann et al., "Length Variation of Helix III in a Hammerhead Ribozyme and Its Influence on Cleavage Activity," <i>Antisense &amp; Nucleic Acid Drug Development</i> 9:25-31 (1999)
	*	Hammond et al., "An RNA-Directed Nuclease Mediates Post-Transcriptional Gene Silencing in <i>Drosophila</i> Cells," <i>Nature</i> 404:293-296 (2000)
	*	Hampel and Tritz, "RNA Catalytic Properties of the Minimum (-)sTRSV Sequence," <i>Biochemistry</i> 28:4929-4933 (1989)
	*	Hampel et al., "Hairpin' Catalytic RNA Model: Evidence for Helices and Sequence Requirement for Substrate RNA," <i>Nucleic Acids Research</i> 18:299-304 (1990)
	*	Hanju et al., "Characterization of Alzheimer's $\beta$ -Secretase Protein BACE," <i>The Journal of Biological Chemistry</i> , 275, 21099-21106 (2000)
	*	Harborth et al., "Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing," <i>Antisense and Nucleic Acid Drug Development</i> , 13:83-105 (2003)
	*	Harris et al., "Identification of phosphates involved in catalysis by the ribozyme RNase P RNA," <i>RNA</i> 1:210-218 (1995)
	*	Hartmann et al., "Spontaneous and Cationic Lipid-Mediated Uptake of Antisense Oligonucleotides in Human Monocytes and Lymphocytes," <i>The Journal of Pharmacology and Experimental Therapeutics</i> 285:920-928 (1998)
	*	Haseloff and Gerlach, "Sequences required for self-catalysed cleavage of the satellite RNA of tobacco ringspot virus," <i>Gene</i> 82:43-52 (1989)
	*	Hegg et al., "Kinetics and Thermodynamics of Intermolecular Catalysis by Hairpin Ribozymes," <i>Biochemistry</i> 34:15813-15828 (1995)
<i>↓</i>	*	Hermann and Patel, "Adaptive Recognition by Nucleic Acid Aptamers," <i>Science</i> 287:820-825 (2000)

EXAMINER	<i>Attn:</i>	DATE CONSIDERED
----------	--------------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: March 11, 2004	Group:

AM	*	Herschlag and Cech, "Catalysis of RNA Cleavage by the <i>Tetrahymena thermophila</i> Ribozyme 1. Kinetic Description of the Reaction of an RNA Substrate Complementary to the Active Site," <i>Biochemistry</i> 29:10159-10171 (1990)
	*	Herschlag and Cech, "Catalysis of RNA Cleavage by the <i>Tetrahymena thermophila</i> Ribozyme. 2. Kinetic Description of the Reaction of an RNA Substrate That Forms a Mismatch at the Active Site," <i>Biochemistry</i> 29:10172-10180 (1990)
	*	Hertel et al., "A Kinetic Thermodynamic Framework for the Hammerhead Ribozyme Reaction," <i>Biochemistry</i> 33:3374-3385 (1994)
	*	Hertel et al., "Numbering System for the Hammerhead," <i>Nucleic Acids Research</i> 20:3252 (1992)
	*	Hofland and Huang, "Formulation and Delivery of Nucleic Acids," <i>Handbook of Exp. Pharmacol.</i> 137:165-192 (1999)
	*	Hudson et al., "Cellular Delivery of Hammerhead Ribozymes Conjugated to a Transferrin Receptor Antibody," <i>Int'l Jour. of Pharmaceutics</i> 182:49-58 (1999)
	*	Hunziker et al., "Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods," <i>VCH</i> , 331-417
	*	Hussain et al., "Identification of a Novel Aspartic Protease (Asp 2) as $\beta$ -Secretase," <i>Molecular and Cellular Neuroscience</i> , 14, 419-427 (1999)
	*	Hutvagner and Zamore, "A MicroRNA in a Multiple-Turnover RNAi Enzyme Complex," <i>Science</i> 297:2056-2060 (2002)
	*	Hutvagner et al., "A Cellular Function for the RNA-Interference Enzyme Dicer in the Maturation of the <i>let-7</i> Small Temporal RNA," <i>Science</i> 293:834-838 (2001)
	*	International Search Report for PCT/US03/04710 mailed November 18, 2003
	*	International Search Report for PCT/US03/05028 mailed October 17, 2003
Y	*	International Search Report for PCT/US03/05346 mailed October 17, 2003
Y	*	International Search Report mailed November 19, 2003 for PCT/US03/18911

EXAMINER <i>AM</i>	DATE CONSIDERED <i>9/26/04</i>
-----------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: March 11, 2004	Group:

OHB	*	Ishiwata et al., "Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholestryl Ether," <u>Chem. Pharm. Bull.</u> 43:1005-1011 (1995) (mistakenly referred to as Ishiwataet)
	*	Ishizaka et al., "Isolation of Active Ribozymes from an RNA Pool of Random Sequences Using an Anchored Substrate RNA," <u>Biochemical and Biophysical Research Communication</u> 214(2):403-409 (1995)
23	Izant and Weintraub, "Constitutive and Conditional Suppression of Exogenous and Endogeneous Genes by Anti-Sense RNA," <u>Science</u> 229:345-352 (1985)	
	*	Jarvis et al., "Optimizing the Cell Efficacy of Synthetic Ribozymes," <u>Journal of Biological Chemistry</u> 271:29107-29112 (1996)
	*	Jaschke et al., "Automated Incorporation of Polyethylene Glycol into Synthetic Oligonucleotides," <u>Tetrahedron Letters</u> 34:301-304 (1993) (sometimes mistakenly referred to as Jschke)
	*	Jaschke et al., "Synthesis and Properties of Oligodeoxyribonucleotide-polyethylene Glycol Conjugates," <u>Nucleic Acids Research</u> 22:4810-4817 (1994)
	*	Jaschke, "Oligonucleotide-Poly(ethylene glycol) Conjugates: Synthesis, Properties, and Application," <u>American Chemical Society</u> 680:265-283 (1997)
	*	Jayasena, "Aptamers: An Emerging Class of Molecules that Rival Antibodies in Diagnostics," <u>Clinical Chemistry</u> 45:1628-1650 (1999)
	*	Jenuwein, "An RNA-Guided Pathway for the Epigenome," <u>Science</u> 297:2215-2218 (2002)
	*	Jolliet-Riant and Tillement, "Drug transfer across the blood-brain barrier and improvement of brain delivery," <u>Fundam. Clin. Pharmacol.</u> 13:16-26 (1999)
	*	Joseph et al., "Substrate selection rules for the hairpin ribozyme determined by in vitro selection, mutation, and analysis of mismatched substrates," <u>Genes &amp; Development</u> , 7:130-138 (1993)
↓	*	Joyce et al., "Amplification, mutation and selection of catalytic RNA," <u>Gene</u> 82:83-87 (1989)

EXAMINER		DATE CONSIDERED	
----------	---	-----------------	---

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(Use several sheets if necessary)			
		Applicant: McSwiggen et al.	
		Filing Date: March 11, 2004	Group:

(AttB)	<ul style="list-style-type: none"> <li>* Joyce, "Directed Molecular Evolution," <i>Scientific American</i> 267:90-97 (1992)</li> <li>* Karle et al., "Differential Changes in Induced Seizures After Hippocampal Treatment of Rats with an Antisense Oligodeoxynucleotide to the GABA<sub>A</sub> Receptor <math>\gamma 2</math> Subunit," <i>Euro. Jour. of Pharmacology</i> 340:153-160 (1997)</li> <li>* Karpeisky et al, "Highly Efficient Synthesis of 2'-O-Amino Nucleosides And Their Incorporation in Hammerhead Ribozymes," <i>Tetrahedron Letters</i> 39:1131-1134 (1998)</li> <li>24 Kashani-Sabet et al., "Reversal of the Malignant Phenotype by an Anti-ras Ribozyme," <i>Antisense Research &amp; Development</i> 2:3-15 (1992)</li> <li>* Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i>," <i>Nature</i> 362:841-844 (1993)</li> <li>* Knitt et al., "ph Dependencies of the <i>Tetrahymena</i> Ribozyme Reveal an Unconventional Origin of an Apparent pK<sub>a</sub>," <i>Biochemistry</i> 35:1560-1570 (1996)</li> <li>* Koch et al., "Vascular Endothelial Growth Factor," <i>Journal of Immunology</i>, 152:4149-4156 (1994)</li> <li>* Koike et al., "Thimet Oligopeptidase Cleaves the Full-Length Alzheimer Amyloid Precursor Protein at a <math>\beta</math>-Secretase Cleavage Site in COS Cells," <i>J. Biochem.</i>, 126, 235-242 (1999)</li> <li>* Kore, et al., "Sequence specificity of the hammerhead ribozyme revisited; the NIH rule," <i>Nucleic Acids Research</i>, 26(18):4116-4120 (1998).</li> <li>* Kronenwett et al., "Oligodeoxyribonucleotide Uptake in Primary Human Hematopoietic Cells is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset," <i>Blood</i> 91:852-862 (1998)</li> <li>* Kumar and Ellington, "Artificial evolution and natural ribozymes," <i>FASEB J.</i> 9:1183-1195 (1995)</li> <li>* Kunath et al., "The structure of PEG-modified poly(ethylene imines) influences biodistribution and pharmacokinetics of their complexes with NF-kappaB decoy in mice.," <i>Medline (Pharm Res.)</i> 19(6): 810-817 (6/1/2002)</li> </ul>
--------	---

EXAMINER <i>AttB</i>	DATE CONSIDERED <i>7/6/05</i>
-------------------------	----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		04-183 (400/147)	10/798,090	
(Use several sheets if necessary)		Applicant: McSwiggen et al.		
		Filing Date:	Group:	
		March 11, 2004		

AHB	* 1	Kusser, "Chemically modified nucleic acid aptamers for in vitro selections: evolving evolution," <i>Reviews in Molecular Biotechnology</i> 74:27-38 (2000)
		Kuwabara et al., "Allosterically Controllable Ribozymes with Biosensor Functions," <i>Current Opinion in Chem. Biol.</i> 4:669-677 (2000)
AHB	* 2	Lasic and Needham "The 'Stealth' Liposome: A Prototypical Biomaterial," <i>Chemical Reviews</i> 95:2601-2627 (1995)
		Lasic and Papahadjopoulos, "Liposomes Revisited," <i>Science</i> 267:1275-1276 (1995)
AHB	* 3	Lee and Larson, "Modified Liposome Formulations for Cytosolic Delivery of Macromolecules," <i>ACS Symposium Series</i> 752:184-192 (2000)
		Lee and Lee, "Preparation of Cluster Glycosides of N-Acetylgalactosamine That Have Subnanomolar Binding Constants Towards the Mammalian Hepatic Gal/GalNAc-specific Receptor," <i>Glyconjugates J.</i> 4:317-328 (1987)
AHB	* 4	Lee et al., "Enhancing the Catalytic Repertoire of Nucleic Acids: A Systematic Study of Linker Length and Rigidity," <i>Nucleic Acids Research</i> 29:1565-1573 (2001)
		Lee et al., "Expression of Small Interfering RNA's Targeted Against HIV-1 rev Transcripts in Human Cells," <i>Nature Biotechnology</i> 19:500-505 (2002)
AHB	* 5	Leifer et al., "Heterogeneity in the Human Response to Immunostimulatory CpG Oligodeoxynucleotides," <i>Journal of Immunotherapy</i> , 26(4):313-319 (2003)
		Leirdal et al., "Gene silencing in mammalian cells by preformed small RNA duplexes," <i>Biochemical and Biophysical Research Communications</i> , 295, 744-748 (2002)
AHB	* 6	Lendlein et al., "Biodegradable, Elastic Shape-Memory Polymers for Potential Biomedical Applications," <i>Science</i> , 296, 1673-1676 (2002)
		Lepri et al., "Effect of Low Molecular Weight Heparan Sulphate on Angiogenesis in the Rat Cornea after Chemical Cauterization," <i>Journal of Ocular Pharmacology</i> 10:273-281 (1994)
AB	27	L'Huillier et al., "Cytoplasmic Delivery of Ribozymes Leads to Efficient Reduction in $\alpha$ -Lactalbumin mRNA Levels in C1271 Mouse," <i>EMBO J.</i> 11:4411-4418 (1992)

EXAMINER	AB	DATE CONSIDERED	7/26/05
----------	----	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: March 11, 2004	Group:



Attn: B	*	Li and Altman, "Cleavage by RNase P of gene N mRNA reduces bacteriophage $\lambda$ burst size," <i>Nucleic Acids Research</i> 24:835-842 (1996)
	*	Li et al., "Thermodynamic and Activation Parameters for Binding of a Pyrene-Labeled Substrate by the <i>Tetrahymena</i> Ribozyme: Docking is Not Diffusion-Controlled and is Driven by a Favorable Entropy Change," <i>Biochemistry</i> 34:14394-14399 (1995)
28	*	Li et al., "Progress toward generating a ferret model of cystic fibrosis by somatic cell nuclear transfer," <i>Reproductive Biology and Endocrinology</i> , 1:83 (2003)
	*	Lichner et al., "Double-stranded RNA-binding proteins could suppress RNA interference-mediated antiviral defences," <i>Journal of General Virology</i> , 84, 975-980 (2003)
29	*	Lieber et al., "Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase," <i>Methods Enzymol.</i> 217:47-66 (1993)
	*	Limbach et al., "Summary: the modified nucleosides of RNA," <i>Nucleic Acids Research</i> 22(12):2183-2196 (1994)
	*	Lin and Matteucci, "A Cytosine Analogue Capable of Clamp-Like Binding to a Guanine in Helical Nucleic Acid," <i>J. Am. Chem. Soc.</i> 120:8531-8532 (1998)
	*	Lin et al., "A Novel mRNA-cRNA Interference Phenomenon for Silencing bcl-2 Expression in Human LNCaP Cells," <i>Biochemical and Biophysical Research Communications</i> , 281, 639-644 (2001)
	*	Lin et al., "Human aspartic protease memapsin 2 cleaves the $\beta$ -secretase site of $\beta$ -amyloid precursor protein," <i>PNAS</i> , 97, 1456-1460 (2000)
	*	Lin et al., "Policing rogue genes," <i>Nature</i> , 402, 128-129 (1999)
	*	Lindgren et al., "Translocation Properties of Novel Cell Penetrating Transportan and Penetratin Analogues," <i>Bioconjugate Chem.</i> 11:619-626 (2000)
✓	*	Lisacek et al., "Automatic Identification of Group I Intron Cores in Genomic DNA Sequences," <i>J. Mol. Biol.</i> 235:1206-1217 (1994)

EXAMINER	Attn: B	DATE CONSIDERED	7/20/08
----------	---------	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				
(Use several sheets if necessary)				
		Applicant: McSwiggen et al.		
		Filing Date: March 11, 2004	Group:	

 	30	Lisziewicz et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication by Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS," <u>Proc. Natl. Acad. Sci. U.S.A.</u> 90:8000-8004 (1993)
	*	Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," <u>J. Biol. Chem.</u> 270(42):24864-24870 (1995)
	*	Liu et al., "Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA," <u>Gene Therapy</u> , 6, 1258-1266 (1999)
	*	Loakes, "The Applications of Universal DNA Base Analogues," <u>Nucleic Acids Research</u> 29:2437-2447 (2001)
	*	Long and Uhlenbeck, "Kinetic characterization of intramolecular and intermolecular hammerhead RNAs with stem II deletions," <u>Proc. Natl. Acad. Sci. USA</u> 91:6977-6981 (1994)
	*	Ma and Wei, "Enhanced Delivery of Synthetic Oligonucleotides to Human Leukaemic Cells by Liposomes and Immunoliposomes," <u>Leukemia Research</u> 20:925-930 (1996)
	*	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach," <u>Biochemistry</u> 32:1751-1758 (1993)
	*	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach. 2. Generation of Covalently Closed, Double-Stranded Cyclic HIV-1 TAR RNA Analogs with High Tat-Binding Affinity," <u>Nucleic Acids Research</u> 21:2585-2589 (1993)
	*	Maher et al., "Kinetic Analysis of Oligodeoxyribonucleotide-Directed Triple-Helix Formation on DNA," <u>Biochemistry</u> 29:8820-8826 (1990)
	*	Martinez et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," <u>Cell</u> 110:563-574 (2002)
	*	Matulic-Adamic et al., "Functionalized Nucleoside 5'-triphosphates for In Vitro Selection of New Catalytic Ribonucleic Acids," <u>Bioorganic &amp; Medicinal Chemistry Letters</u> 10:1299-1302 (2000)

EXAMINER 	DATE CONSIDERED 
--	---

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: March 11, 2004	Group:

AttB	•	Maurer et al., "Lipid-based systems for the intracellular delivery of genetic drugs," <i>Molecular Membrane Biology</i> 16:129-140 (1999)
		McCurdy et al., "Deoxyoligonucleotides with Inverted Polarity: Synthesis and Use in Triple-Helix Formation" <i>Nucleosides &amp; Nucleotides</i> 10:287-290 (1991)
31	•	McGarry and Lindquist, "Inhibition of heat shock protein synthesis by heat-inducible antisense RNA," <i>Proc. Natl. Acad. Sci. USA</i> 83:399-403 (1986)
	•	McKay, "Structure and function of the hammerhead ribozyme: an unfinished story," <i>RNA</i> 2:395-403 (1996)
	•	McManus et al., "Gene Silencing Using Micro-RNA Designed Hairpins," <i>RNA</i> 8:842-850 (2002)
	•	Mesmaeker et al, "Novel Backbone Replacements for Oligonucleotides," <i>American Chemical Society</i> , pp. 24-39 (1994)
	•	Michel and Westhof, "Slippery substrates," <i>Nat. Struct. Biol.</i> 1:5-7 (1994)
	•	Michel et al., "Structure and Activities of Group II Introns," <i>Annu. Rev. Biochem.</i> 64:435-461 (1995)
	•	Michels and Pyle, "Conversion of a Group II Intron into a New Multiple-Turnover Ribozyme that Selectively Cleaves Oligonucleotides: Elucidation of Reaction Mechanism and Structure/Function Relationships," <i>Biochemistry</i> 34:2965-2977 (1995)
	•	Milner et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays," <i>Nature Biotechnology</i> 15:537-541 (1997)
32	•	Miyagishi and Taira, "U6 Promoter-driven siRNAs with Four Uridine 3' Overhangs Efficiently Suppress Targeted Gene Expression in Mammalian Cells," <i>Nature Biotechnology</i> 19:497-500 (2002)
	•	Mohr et al., "A tyrosyl-tRNA synthetase can function similarly to an RNA structure in the <i>Tetrahymena</i> ribozyme," <i>Nature</i> 370:147-150 (1994)
✓	•	Moore and Sharp, "Site-Specific Modification of Pre-mRNA: The 2'-Hydroxyl Groups at the Splice Sites," <i>Science</i> 256:992-996 (1992)

EXAMINER <i>AttB</i>	DATE CONSIDERED <i>3/27/05</i>
-------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: McSwiggen et al.	
(Use several sheets if necessary)		Filing Date: March 11, 2004	Group:

Attn:	*	Mori et al., "Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization," <i>Journal of Cellular Physiology</i> , 118(2) 253-263 (2001)
	*	Morris et al., "A New Peptide Vector for Efficient Delivery of Oligonucleotides into Mammalian Cells," <i>Nucleic Acids Research</i> 25:2730-2736 (1997)
	*	Nakamaye and Eckstein, "AUA-Cleaving Hammerhead Ribozymes: Attempted Selection for Improved Cleavage," <i>Biochemistry</i> 33:1271-1277 (1994)
	*	Nathans and Smith, "Restriction Endonucleases in the Analysis and Restructuring of DNA Molecules," <i>Ann. Rev. Biochem.</i> 44:273-293 (1975)
	*	Nomura et al., "Development of an Efficient Intermediate, $\alpha$ -[2-(Trimethylsilyl) ethoxy]-2-N-[2-trimethylsilyl]ethoxycarbonyl]folic Acid, for the Synthesis of Folate ( $\gamma$ )-Conjugates, and Its Application to the Synthesis of Folate-Nucleoside Conjugates," <i>J. Org. Chem.</i> 65:5016-5021 (2000)
	33	Noonberg et al., <i>In vivo</i> generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation," <i>Nucleic Acids Research</i> 22(14):2830-2836 (1994)
	*	Noviello et al., "Autosomal Recessive Hypercholesterolemia Protein Interacts with and Regulates the Cell Surface Level of Alzheimer's Amyloid $\beta$ Precursor Protein*," <i>The Journal of Biological Chemistry</i> , 278, 31843-31847 (2003)
	34	Novina et al., "siRNA-Directed Inhibition of HIV-1 Infection," <i>Nature Medicine</i> 8:7, 681-686 (2002)
	*	Nykanen et al., "ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway," <i>Cell</i> 107:309-321 (2001)
	35	Ohkawa et al., "Activities of HIV-RNA Targeted Ribozymes Transcribed From a 'Shot-Gun' Type Ribozyme-trimming Plasmid," <i>Nucleic Acids Symp. Ser.</i> 27:15-16 (1992)
↓	*	Ohno-Matsui et al., "Inducible Expression of Vascular Endothelial Growth Factor in Adult Mice Causes Severe Proliferative Retinopathy and Retinal Detachment," <i>Am. J. Pathology</i> , 160, 711-719 (2002)

EXAMINER	Attn:	DATE CONSIDERED
----------	-------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)		U.S. Department of Commerce Patent and Trademark Office	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
		Applicant: McSwiggen et al.	
		Filing Date: March 11, 2004	Group:

<i>Alt B</i>	36	Ojwang et al., "Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin Ribozyme," <i>Proc. Natl. Acad. Sci. USA</i> 89:10802-10806 (1992)
	*	Oku et al., "Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography," <i>Biochimica et Biophysica Acta</i> 1238:86-90 (1995)
	*	Ono et al., "DNA Triplex Formation of Oligonucleotide Analogs Consisting of Linker Groups and Octamer Segments That Have Opposite Sugar-Phosphate Backbone Polarities," <i>Biochemistry</i> 30:9914-9921 (1991)
	*	O'Reilly et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <i>Cell</i> 79:315-328 (1994)
	*	Orgis et al., "DNA/polyethylenimine transfection particles: Influence of ligands, polymer size, and PEGylation on internalization and gene expression," <i>AAPS PharmSci.</i> , 3 (3) article 21 ( <a href="http://www.pharmsci.org">http://www.pharmsci.org</a> ) p. 1- 11 (2001)
	*	Ormerod et al., "Effects of Altering the Eicosanoid Precursor Pool on Neovascularization and Inflammation in the Alkali-burned Rabbit Cornea," <i>American Journal of Pathology</i> 137:1243-1252 (1990)
	*	Pal-Bhadra et al., "Heterochromatic Silencing and HP1 Localization in Drosophila Are Dependent on the RNAi Machinery," <i>Science</i> , 303, 669-672 (2004)
	*	Pan et al., "Probing of tertiary interactions in RNA: 2'-Hydroxyl-base contacts between the Rnase P and pre-tRNA," <i>Proc. Natl. Acad. Sci. USA</i> 92:12510-12514 (1995)
	*	Pandey et al., "Role of B61, the Ligand for the Eck Receptor Tyrosine Kinase, in TNF- $\alpha$ -Induced Angiogenesis," <i>Science</i> 268:567-569 (1995)
	*	Pardridge et al., "Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 92:5592-5596 (1995)
<i>✓</i>	*	Parrish, "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference," <i>Molecular Cell</i> 6:1077-1087 (2000)

EXAMINER <i>Alt B</i>	DATE CONSIDERED <i>3/21/05</i>
-----------------------	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			04-183 (400/147)	10/798,090
(Use several sheets if necessary)			Applicant:	
			McSwiggen et al.	
			Filing Date:	Group:
			March 11, 2004	

<p style="margin: 0;"><i>Attn:</i></p> <p style="margin: 0;">37</p> <p style="margin: 0;">↓</p>	<p>Passaniti et al., "A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor," <i>Laboratory Investigation</i> 67:519-528 (1992)</p>
	<p>Paul et al., "Effective Expression of Small Interfering RNA in Human Cells," <i>Nature Biotechnology</i> 20:505-508 (2002)</p>
	<p>Perreault et al., "Mixed Deoxyribo- and Ribo-Oligonucleotides with Catalytic Activity," <i>Nature</i> 344:565-567 (1990) (often mistakenly listed as Perrault)</p>
	<p>Perrotta and Been, "A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA," <i>Nature</i> 350:434-436 (1991)</p>
	<p>Perrotta and Been, "Cleavage of Oligoribonucleotides by a Ribozyme Derived from the Hepatitis δ Virus RNA Sequence," <i>Biochemistry</i> 31:16-21 (1992)</p>
	<p>Petersen et al., "Polyethylenimine-graft-Poly(ethylene glycol) Copolymers: Influence of Copolymer Block Structure on DNA Complexation and Biological Activities as Gene Delivery System," <i>Bioconjugate Chem.</i>, 13, 845-854 (2002)</p>
	<p>Pieken et al., "Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," <i>Science</i> 253:314-317 (1991)</p>
	<p>Pierce et al., "Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization," <i>Proc. Natl. Acad. Sci. USA</i> 92:905-909 (1995)</p>
	<p>Player and Torrence, "The 2-5A System: Modulation of Viral and Cellular Processes Through Acceleration of RNA Degradation," <i>Pharmacol Ther.</i> 78:55-113 (1998)</p>
	<p>Ponpipom et al., "Cell-Specific Ligands for Selective Drug Delivery to Tissues and Organs," <i>J. Med. Chem.</i> 24:1388-1395 (1981)</p>
	<p>Praseuth et al., "Triple helix formation and the antigen for sequence-specific control of gene expression," <i>Biochimica et Biophysica Acta</i> 1489:181-206 (1999)</p>
	<p>Puttaraju et al., "A circular trans-acting hepatitis delta virus ribozyme," <i>Nucleic Acids Research</i> 21:4253-4258 (1993)</p>

EXAMINER <i>Attn:</i>	DATE CONSIDERED <i>3/28/05</i>
-----------------------	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: March 11, 2004	Group:

AHLB	*	Pyle et al., "Building a Kinetic Framework for Group II Intron Ribozyme Activity: Quantitation of Interdomain Binding and Reaction Rate," <u>Biochemistry</u> 33:2716-2725 (1994)
	*	Rajakumar et al., "Effects of Intrastriatal Infusion of D <sub>2</sub> Receptor Antisense Oligonucleotide on Apomorphine-Induced Behaviors in the Rat," <u>Synapse</u> 26:199-208 (1997)
	*	Randall et al., "Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs," <u>PNAS</u> , 100, 235-240 (2003)
	*	Reinhart and Bartel, "Small RNAs Correspond to Centromer Heterochromatic Repeats," <u>Science</u> 297:1831 (2002)
	*	Reinhart et al., "MicroRNAs in Plants," <u>Genes &amp; Development</u> 16:1616-1626 (2002)
38		Reynolds et al., "Rational siRNA design for RNA interference," <u>Nature Biotechnology</u> , 22, 3, 326-330 (2004)
	*	Richardson and Schepartz, "Tethered Oligonucleotide Probes. A Strategy for the Recognition of Structured RNA," <u>J. Am. Chem. Soc.</u> 113:5109-5111 (1991)
	*	Robertson et al., "Purification and Properties of a Specific <i>Escherichia coli</i> Ribonuclease which Cleaves a Tyrosine Transfer Ribonucleic Acid Precursor," <u>J. Biol. Chem.</u> 247:5243-5251 (1972)
	*	Rossi et al., "Ribozymes as Anti-HIV-1 Therapeutic Agents: Principles, Applications, and Problems," <u>Aids Research and Human Retroviruses</u> 8:183-189 (1992)
	*	Ruosahti, "RGD and Other Recognition Sequences for Integrins," <u>Annu. Rev. Cell Dev. Biol.</u> 12:697-715 (1996)
↓	*	Saenger (ed), "Modified Nucleosides and Nucleotides; Nucleoside Di- and Triphosphates; Coenzymes and Antibiotics, (ch.7)" <u>Principles of Nucleic Acid Structure</u> 158-200 (1984)

EXAMINER <i>AHLB</i>	DATE CONSIDERED <i>Mar 10</i>
-------------------------	----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			04-183 (400/147)	10/798,090
(Use several sheets if necessary)			Applicant: McSwiggen et al.	
			Filing Date:	Group:
			March 11, 2004	

ATTB	•	Salo et al., "Aminooxy Functionalized Oligonucleotides: Preparation, On-Support Derivatization, and Postsynthetic Attachment to Polymer Support," <u>Bioconjugate Chem.</u> 10:815-823 (1999)
		Sanghvi et al., "Improved Process for the Preparation of Nucleosidic Phosphoramidites Using a Safer and Cheaper Activator," <u>Organic Process Res. &amp; Dev.</u> 4:175-181 (2000)
	•	Santoro and Joyce, "A general purpose RNA-cleaving DNA enzyme," <u>Proc. Natl. Acad. Sci. USA</u> 94:4262-4266 (1997)
	•	Santoro et al., "Mechanism and Utility of an RNA-Cleaving DNA Enzyme," <u>Biochemistry</u> 37:13330-13342 (1998)
	•	Santoro et al., "RNA Cleavage by a DNA Enzyme with Extended Chemical Functionality," <u>J. Am. Chem. Soc.</u> 122:2433-2439 (2000)
39	•	Sarver et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents" <u>Science</u> 247:1222-1225 (1990)
	•	Saville and Collins, "A Site-Specific Self-Cleavage Reaction Performed by a Novel RNA In <i>Neurospora</i> Mitochondria," <u>Cell</u> 61:685-696 (1990)
	•	Saville and Collins, "RNA-Mediated Ligation of Self-Cleavage Products of a <i>Neurospora</i> Mitochondrial Plasmid Transcript," <u>Proc. Natl. Acad. Sci. USA</u> 88:8826-8830 (1991)
40	•	Scanlon et al., "Ribozyme-Mediated Cleavage of c-fos mRNA Reduces Gene Expression of DNA Synthesis Enzymes and Metallothionein," <u>Proc. Natl. Acad. Sci. USA</u> 88:10591-10595 (1991)
	•	Scaringe et al., "Chemical synthesis of biologically active oligoribonucleotides using $\beta$ -cyanoethyl protected ribonucleoside phosphoramidites," <u>Nucl Acids Res.</u> 18:5433-5441 (1990)
✓	•	Schmajuk et al., "Antisense Oligonucleotides with Different Backbones," <u>The Journal of Biological Chemistry</u> 274:21783-21789 (1999)

EXAMINER	ATTB	DATE CONSIDERED
----------	------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)			
<b>Applicant:</b> McSwiggen et al.			
<b>Filing Date:</b> March 11, 2004		<b>Group:</b>	

Akb	*	Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," <i>Nucleic Acids Research</i> 24:573-581 (1996)
	*	Schroeder et al., "Diffusion Enhancement of Drugs by Loaded Nanoparticles in Vitro," <i>Prog. Neuro-Psychopharmacol. &amp; Biol. Psychiat.</i> 23:941-949 (1999) [sometimes cited by RPI as <i>Prog Neuropsychopharmacol Biol Psychiatry</i> 23:941-949, 1999]
	*	Schwarz et al., "Evidence that siRNAs Function as Guides, Not Primers, in the <i>Drosophila</i> and Human RNAi Pathways," <i>Molecular Cell</i> 10:537-548 (2002)
41	*	Schwarz et al., "Asymmetry in the Assembly of the RNAi Enzyme Complex," <i>Cell</i> , 1115, 199-208 (2003)
	*	Schwarze et al., "In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse," <i>Science</i> 285:1569-1572 (1999)
	*	Scott et al., "The crystal structure of an All-RNA hammerhead ribozyme: A proposed mechanism for RNA catalytic cleavage," <i>Cell</i> 81:991-1002 (1995)
	*	Seela and Kaiser, "Oligodeoxyribonucleotides containing 1,3-propanediol as nucleoside substitute," <i>Nucleic Acids Research</i> 15:3113-3129 (1987)
	*	Segarra et al., "Molecular characterization of the <i>Enterococcus faecalis</i> cytolysin activator," <i>Infection and Immunity</i> , 59, 4, 1239-1246 (1991) Database CAPLUS on STN, AN:1992:230597
	*	Senger et al., "Vascular permeability factor (VPF, VEGF) in tumor biology," <i>Cancer and Metastasis Reviews</i> 12:303-324 (1993)
	*	Shabarova et al., "Chemical ligation of DNA: The first non-enzymatic assembly of a biologically active gene," <i>Nucleic Acids Research</i> 19:4247-4251 (1991)
	*	Sharp et al., "RNAi and double-strand RNA," <i>Genes &amp; Development</i> , 13:139-141 (1999)
V	*	Sheehan et al., "Biochemical properties of phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides," <i>Nucleic Acids Research</i> , 31 (14), 4109-4118 (2003)

EXAMINER	<i>Akb</i>	DATE CONSIDERED	<i>3/27/05</i>
----------	------------	-----------------	----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: March 11, 2004	Group:

OHB	42	Shimizu et al., "A Mechanism of Antigen-induced Mucus Production in Nasal Epithelium of Sensitized Rats," <i>Am J Respir Crit Care Med.</i> , 161, 1648-1654 (2000)
	*	Shweiki et al., "Patterns of Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Mice Suggest a Role in Hormonally Regulated Angiogenesis," <i>J. Clin. Invest.</i> 91:2235-2243 (1993)
	*	Silverman et al., "Selective RNA Cleavage by Isolated RNase L Activated with 2'-5A Antisense Chimeric Oligonucleotides," <i>Methods in Enzymology</i> 313:522-533 (1999)
	*	Simantov et al., "Dopamine-Induced Apoptosis in Human Neuronal Cells: Inhibition by Nucleic Acids Antisense to the Dopamine Transporter," <i>Neuroscience</i> 74(1):39-50 (1996)
	43	Snyder et al., "Defining Genes in the Genomics Era," <i>Science</i> , 300, 258-260 (2003)
	*	Sommer et al., "The Spread and Uptake Pattern of Intracerebrally Administered Oligonucleotides in Nerve and Glial Cell Populations of the Rat Brain," <i>Antisense &amp; Nucleic Acid Drug Development</i> 8:75-85 (1998)
	44	Spector Ed., 1999, Anticholinergic Agents in the Upper and Lower Airways, 1999, Vol. 134, p. 16-17
	*	Stein and Cheng, "Antisense Oligonucleotides as Therapeutic Agents - Is the Bullet Really Magical?" <i>Science</i> 261:1004-1288 (1993)
	*	Stein et al., "A Specificity Comparison of Four Antisense Types: Morpholino, 2'-O-Methyl RNA, DNA, and Phosphorothioate DNA," <i>Antisense &amp; Nucleic Acid Drug Development</i> 7:151-157 (1997)
↓	*	Strauss, Evelyn, "Molecular Biology: Candidate 'Gene Silencers' Found," <i>Molecular Biology</i> , Vol. 286, No. 5441, p. 886 (1999) [sometimes mistakenly referred to as being published in <i>Science</i> ]
✓	*	Strobel and Dervan, "Site-Specific Cleavage of a Yeast Chromosome by Oligonucleotide-Directed Triple-Helix Formation," <i>Science</i> 249:73-75 (1990)

EXAMINER	<i>OHB</i>	DATE CONSIDERED	<i>7/29/05</i>
----------	------------	-----------------	----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)			
<b>Applicant:</b> McSwiggen et al.			
<b>Filing Date:</b> March 11, 2004		<b>Group:</b>	

AAB	*	Strobel et al., "Exocyclic Amine of the Conserved G-U Pair at the Cleavage Site of the <i>Tetrahymena</i> Ribozyme Contributes to 5'-Splice Site Selection and Transition State Stabilization," <i>Biochemistry</i> 35:1201-1211 (1996)
	*	Strobel et al., "Minor Groove Recognition of the Conserved G-U Pair at the <i>Tetrahymena</i> Ribozyme Reaction Site," <i>Science</i> 267:675-679 (1995)
45		Sugimoto et al., "A new model of allergic rhinitis in rats by topical sensitization and evaluation of H1-receptor antagonists," <i>Immunopharmacology</i> , 38, 1-7 (2000)
	*	Sullenger and Cech, "Ribozyme-mediated repair of defective mRNA by targeted trans-splicing," <i>Nature</i> 371:619-622 (1994)
	46	Sullenger and Cech, "Tethering Ribozymes to a Retroviral Packaging Signal for Destruction of Viral RNA," <i>Science</i> 262:1566-1569 (1993)
	*	Sullenger et al., "Overexpression of TAR Sequences Renders Cells Resistant to Human Immunodeficiency Virus Replication," <i>Cell</i> 63:601-608 (1990)
	*	Sun, "Technology evaluation: SELEX, Giliad Sciences Inc," <i>Current Opinion in Molecular Therapeutics</i> 2:100-105 (2000)
	*	Szostak and Ellington, "Ch. 20 - In Vitro Selection of Functional RNA Sequences," in <i>The RNA World</i> , edited by Gesteland and Atkins, Cold Spring Harbor Laboratory Press, pp. 511-533 (1993)
	*	Szostak, "In Vitro Genes," <i>TIBS</i> 17:89-93 (1993)
47		Taira et al., "Construction of a novel RNA-transcript-trimming plasmid which can be used both <i>in vitro</i> in place of run-off and (G)-free transcriptions and <i>in vivo</i> as multi-sequences transcription vectors," <i>Nucleic Acids Research</i> 19:5125-5130 (1991)
	*	Takahashi et al., "Markedly Increased Amounts of Messenger RNAs for Vascular Endothelial Growth Factor and Placenta Growth Factor in Renal Cell Carcinoma Associated with Angiogenesis," <i>Cancer Research</i> 54:4233-4237 (1994)
V	*	Tang et al., "Examination of the catalytic fitness of the hammerhead ribozyme by <i>in vitro</i> selection," <i>RNA</i> 3:914-925 (1997)

EXAMINER	<i>AAB</i>	DATE CONSIDERED	<i>3/11/04</i>
----------	------------	-----------------	----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
			04-183 (400/147)	10/798,090
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)				
		<b>Applicant:</b> McSwiggen et al.		
		<b>Filing Date:</b> March 11, 2004	<b>Group:</b>	

AHP	*	Thomas et al., "Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells," <i>PNAS</i> , 99, 14640-14645 (2002)
	48	Thompson et al., "Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter," <i>Nucleic Acids Research</i> 23:2259-2268 (1995)
	*	Torrence et al., "Targeting RNA for degradation with a (2'-5') oligoadenylate-antisense chimera," <i>Proc. Natl. Acad. Sci. USA</i> 90:1300-1304 (1993)
	*	Turner et al., "Improved Parameters for Prediction of RNA Structure," <i>Cold Spring Harbor Symposia on Quantitative Biology</i> Volume LII, pp. 123-133 (1987)
	*	Turner et al., "Free Energy Increments for Hydrogen Bonds in Nucleic Acid Base Pairs," <i>J. Am. Chem. Soc.</i> 109:3783-3785 (1987)
	*	Tuschl et al., "Small Interfering RNAs: A Revolutionary Tool for Analysis of Gene Function and Gene Therapy," <i>Molecular Interventions</i> , 295, 3, 158-167 (2002)
	*	Tuschl et al., "Targeted mRNA Degradation by Double-Stranded RNA In Vitro," <i>Genes &amp; Development</i> 3191-3197 (1999)
	*	Tuschl, "RNA Interference and Small Interfering RNAs," <i>ChemBioChem</i> 2:239-245 (2001)
	*	Tyler et al., "Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression," <i>Proc. Natl. Acad. Sci. USA</i> 96:7053-7058 (1999)
	*	Tyler et al., "Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo," <i>FEBS Letters</i> 421:280-284 (1998)
	*	Uhlmann and Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," <i>Chemical Reviews</i> 90:544-584 (1990)
	49	Ui-Tei et al., "Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference," <i>Nucleic Acids Research</i> , 32, 3, 936-948 (2004)
↓	*	Usman and Cedergren, "Exploiting the chemical synthesis of RNA," <i>TIBS</i> 17:334-339 (1992)

EXAMINER	<i>AHP</i>	DATE CONSIDERED	<i>3/27/05</i>
----------	------------	-----------------	----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: March 11, 2004	Group:

Att B	*	Usman et al., "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support: Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an <i>Escherichia coli</i> Formylmethionine tRNA," <i>J. Am. Chem. Soc.</i> 109:7845-7854 (1987)
	*	Usman et al., "Chemical modification of hammerhead ribozymes: activity and nuclease resistance," <i>Nucleic Acids Symposium Series</i> 31:163-164 (1994)
	*	Usman et al., "Hammerhead ribozyme engineering," <i>Current Opinion in Structural Biology</i> 1:527-533(1996)
	*	Vaish et al., "Isolation of Hammerhead Ribozymes with Altered Core Sequences by <i>in Vitro</i> Selection," <i>Biochemistry</i> 36:6495-6501 (1997)
	*	Vassar et al., " $\beta$ -Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE," <i>Science</i> 286:735-741 (1999)
	50	Ventura et al., "Activation of HIV-Specific Ribozyme Activity by Self-Cleavage," <i>Nucleic Acids Research</i> 21:3249-3255 (1993)
	*	Verdel et al., "RNAi-Mediated Targeting of Heterochromatin by the RITS Complex," <i>Science</i> , 303, 672-676 (2004)
	*	Verma and Eckstein, "Modified Oligonucleotides: Synthesis and Strategy for Users," <i>Annu. Rev. Biochem.</i> 67:99-134 (1998)
	*	Volpe et al., "Regulation of Heterochromatic Silencing and Histone H3 Lysine-9 Methylation by RNAi," <i>Science</i> 297:1833-1837 (2002)
	*	Wang et al., "Delivery of Antisense Oligodeoxyribonucleotides Against the Human Epidermal Growth Factor Receptor into Cultured KB Cells with Liposomes Conjugated to Folate via Polyethylene Glycol," <i>Proc. Natl. Acad. Sci. USA</i> 92:3318-3322 (1995)
✓	*	Waterhouse et al., "Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA," <i>Proc. Natl. Acad. Sci. USA</i> , 95, 13959-13964 (1998)

EXAMINER <i>Att B</i>	DATE CONSIDERED <i>3/27/05</i>
--------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)			
<b>Applicant:</b> McSwiggen et al.			
<b>Filing Date:</b> March 11, 2004		<b>Group:</b>	

<i>AKB</i>	51	Weerasinghe et al., "Resistance to Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Human CD4 <sup>+</sup> Lymphocyte-Derived Cell Lines Conferred by Using Retroviral Vectors Expressing an HIV-1 RNA-Specific Ribozyme," <u>Journal of Virology</u> 65:5531-5534 (1994)
	*	Werner and Uhlenbeck, "The effect of base mismatches in the substrate recognition helices of hammerhead ribozymes on binding and catalysis," <u>Nucleic Acids Research</u> 23:2092-2096 (1995)
	*	Wianny and Zernicka-Goetz et al., "Specific Interference with Gene Function by Double-Stranded RNA in Early Mouse Development," <u>Nature Cell Biology</u> 2:70-75 (2000)
	52	Wilder et al., "Dissociation of Airway Hyperresponsiveness from Immunoglobulin E and Airway Eosinophilia in a Murine Model of Allergic Asthma," <u>Am. J. Respir. Cell Mol. Biol.</u> , 20, 1326-1334 (1999)
	*	Wincott et al., "Synthesis, deprotection, analysis and purification of RNA and ribozymes," <u>Nucleic Acids Research</u> 23(14):2677-2684 (1995)
	*	Wincott et al., "A Practical Method for the Production of RNA and Ribozymes," <u>Methods in Molecular Biology</u> 74:59-69 (1997)
	*	Woolf et al., "Specificity of Antisense Oligonucleotides <i>in vivo</i> ," <u>Proc. Natl. Acad. Sci. USA</u> 89:7305-7309 (1992)
	53	Wright et al., "Animal Models of Cigarette Smoke-Induced COPD," <u>Chest</u> , 122:301S-306S (2002)
	*	Wu and Wu, "Receptor-mediated <i>in Vitro</i> Gene Transformation by a Soluble DNA Carrier System," <u>The Journ. of Biol. Chem.</u> 262:4429-4432 (1987)
	*	Wu-Pong et al., "Nucleic Acid Drug Delivery, Part 2; Delivery to the Brain," <u>BioPharm</u> 32-38 (1999)
<i>▼</i>	*	Yamada et al., "Nanoparticles for the delivery of genes and drugs to human hepatocytes," <u>Nature Biology</u> , <i>Published online</i> : 29 June 2003, doi:10.1038/nbt843 (August 2003 Volume 21 Number 8 pp 885-890) (2003)

EXAMINER <i>Attn:</i>	DATE CONSIDERED <i>8/10/03</i>
-----------------------	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-183 (400/147)	Serial No. 10/798,090
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: March 11, 2004	Group:

AT&T	*	Yan et al., "Membrane-anchored Aspartyl Protease with Alzheimer's Disease $\beta$ -Secretase Activity," <i>Nature</i> 402:533-537 (1999)
	*	Yang et al., "Hydrodynamic injection of viral DNA: A mouse model of acute hepatitis B virus infection," <i>PNAS</i> , 99, 21, 13825-13830 (2002)
	54	Yu et al., "A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human Immunodeficiency Virus Type 1," <i>Proc. Natl. Acad. Sci. USA</i> 90:6340-6344 (1993)
	*	Yuan et al., "Targeted cleavage of mRNA by human RNase P," <i>Proc. Natl. Acad. Sci. USA</i> 89:8006-8010 (1992)
	*	Zamore et al., "RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals," <i>Cell</i> 101:25-33 (2000)
	*	Zarrinkar and Williamson, "The P9.1-P9.2 peripheral extension helps guide folding of the <i>Tetrahymena</i> ribozyme," <i>Nucleic Acids Research</i> 24:854-858 (1996)
	55	Zhang et al., "Asthmalike biphasic airway responses in Brown Norway rats sensitized by dermal exposure to dry trimellitic anhydride powder," <i>J. Allergy Clin. Immunol.</i> , 113, 2, 320-326 (2003)
	56	Zhou et al., "Synthesis of Functional mRNA in Mammalian Cells by Bacteriophage T3 RNA Polymerase," <i>Mol. Cell. Biol.</i> 10:4529-4537 (1990)
	*	Ziche et al., "Angiogenesis Can Be Stimulated or Repressed <i>In Vivo</i> by a Change in GM3:GD3 Ganglioside Ratio," <i>Laboratory Investigation</i> 67:711-715 (1992)
	*	Zimmerly et al., "A Group II Intron RNA is a Catalytic Component of a DNA Endonuclease Involved in Intron Mobility," <i>Cell</i> 83:529-538 (1995)
✓	*	Zinnen et al., "Chemically Modified siRNAs: Potential Anti-viral Hepatitis Therapeutics" (Abstract) March 2004

EXAMINER <i>AT&amp;T</i>	DATE CONSIDERED <i>3/27/04</i>
--------------------------	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.